SCHEMBL6613264

SCHEMBL6613264

Cc1ccc(O)c(-c2cc(C3CC3)n(C(=O)NCCc3ccccc3)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.44
▸ LMNA P02545 4/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ MAPK1 P28482 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ GFER P55789 1/20 0.39
▸ POLB P06746 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ MGLL Q99685 1/20 0.38
▸ ASAH1 Q13510 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ KCNJ6 P48051 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6621703 0.88 ALDH1A1 (0.43) LMNANPC1RAB9AMEN1KMT2A
SCHEMBL6615757 0.87 KDM4C (0.40) LMNAMAPTNPSR1NPC1RAB9A
SCHEMBL6617784 0.85 EPHX2 (0.42) HPGDMAPK1ASAH1EPHX2KDM4E
SCHEMBL6618475 0.85 RAB9A (0.42) MAPTTP53NPC1RAB9AMEN1
SCHEMBL6618119 0.85 HPGD (0.41) HPGDLMNAMAPTMAPK1NPC1
SCHEMBL6617950 0.83 LMNA (0.47) LMNAMEN1KMT2APOLBALDH1A1
SCHEMBL6616043 0.83 MAPT (0.43) MAPTTP53MAPK1NPC1RAB9A
SCHEMBL6620003 0.82 RAB9A (0.39) HPGDMAPTNPC1RAB9AMEN1
SCHEMBL6603917 0.82 CHRNA7 (0.36) LMNANPC1RAB9AMEN1KMT2A
SCHEMBL6661397 0.81 CRACR2A (0.45) HPGDMAPTMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458379-A1 HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2004-09-22 — — EP claimed
US-20040010027-A1 Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them PHARMACIA & UPJOHN SPA (IT) 2004-01-15 — — US claimed
WO-2003051358-A1 HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA SPA (IT) 2003-06-26 — — WO claimed
EP-1458379-A1 HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2004-09-22 — — EP disclosed
US-20040010027-A1 Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them PHARMACIA & UPJOHN SPA (IT) 2004-01-15 — — US disclosed
WO-2003051358-A1 HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA SPA (IT) 2003-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010027-A1 Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them CNKSR1, CSNK1A1, CDK6 HPGD 2393/4885LMNA 2464/4885MAPT 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback